department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

SEVELAMER CARBONATE · pharmadog

pharmadog
drugs
SEVELAMER CARBONATE

drug

patient view →

SEVELAMER CARBONATE

Marketedupdated 2mo ago

by TWi Pharmaceuticals USA Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

SEVELAMER CARBONATE

generic

SEVELAMER CARBONATE

indication

Hyperphosphatemia In Chronic Kidney Disease

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 51m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagApproval2 co-mentions · 1 sources
companyNavinta LLC1 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources
drugRenvela1 co-mentions · 1 sources

Trials studying SEVELAMER CARBONATE

phase3AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemiacompletedn=474
phase3FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Diseasecompletedn=98
phase2Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemiarecruitingn=50
phase4Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binderscompletedn=44
phase3Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysiscompletedn=239
phase2A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patientscompletedn=55
phase3A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysiscompletedn=1,559